Drug Approval | February 18, 2022
USFDA accepts Mirati Therapeutics' New Drug Application for Adagrasib
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
Resolv ER may remedy leading causes of blindness in adults
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
Key takeaways of Q3FY22 quarter & conference call highlights
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
The first patient in India treated at Jaslok Hospital and Research Centre, Mumbai Includes the world’s smallest implantable spinal cord stimulator
Subscribe To Our Newsletter & Stay Updated
